Endo Pharmaceuticals Announces Potential for Short Supply of Pain Medicines
In light of the below announcement from Endo, Carlisle Medical has worked with our prescription medication suppliers to ensure we are adequately stocked on all of the medications listed below. With these efforts, we expect to see no impact in our ability to service our patients who are receiving medication from Carlisle Medical Home Delivery Pharmacy.
Please feel free to use Carlisle’s ‘Ask a Pharmacist’ service for any questions or concerns. Pharmacists are available Monday – Friday – 7:30 am to 6:00pm CST and Saturday – 8:00 am to 9:00am CST.
Toll Free Phone
1-800-553-1783
Endo Pharmaceuticals Announces Potential for Short Supply of Pain Medicines Endo Pharmaceuticals today (01/09/12) announced that, as a result of a temporary shut-down of Novartis Consumer Health Inc.’s Lincoln, Neb., manufacturing facility, there will be a short-term supply constraint of OPANA® ER. The company also announced certain other Endo analgesic products manufactured at this facility may experience short-term supply disruptions. Endo is working closely with the U.S. Food and Drug Administration (FDA) and Novartis to minimize patient disruptions and promptly resume production of Endo’s products at the Lincoln facility.
As a result of the Novartis facility shutdown, Endo will be expediting the production of products at alternative manufacturing facilities. Endo has initiated the manufacturing of PERCOCET® and ENDOCET® at its Huntsville, Ala., facility and expects minimal disruption to patients on these products.
The possibility of short-term disruption in supply is expected to affect the following products and possibly all strengths:
• Opana ER®/Opana® (oxymorphone hydrochloride)
• Percocet®/Endocet® (oxycodone/acetaminophen)
• Percodan®/Endodan® (oxycodone/aspirin)
• Zydone® (hydrocodone/acetaminophen)
• oxymorphone hydrochloride
• morphine sulfate ER
Please contact a Carlisle Medical pharmacist at 1-800-553-1783 for further information and see the below web link to the Endo Pharmaceutical’s full press release.
Related Link: http://www.goo.gl/2rPch
